Advanced Gastroesophageal Cancer
Publication Date: January 5, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...Treatment...
...notherapy and Targeted Therapy for Advanced Ga...
...First-line Therapy...
...endation 1.1For HER2-negative patien...
...mmendation 1.2For HER2-negative patients with...
...n 1.3For patients with ESCC and PD...
...commendation 1.4For patients with ESCC, and PD-L...
....5For patients with HER2-positive gastric or...
...Second- or Third-line Th...
Recommendation 2.1For patients with adva...
...ion 2.2For HER2-positive patients...